MLTX as reported
- Net Income
- −$257M
Net Income · +77% year on year · trailing twelve months to Q1 2026
- Free Cash Flow
- −$224M
Free Cash Flow · +60% year on year · trailing twelve months to Q1 2026
- EPS
- −$3.87
EPS · +68% year on year · trailing twelve months to Q1 2026
| Series | Latest | Year on year | As of |
|---|---|---|---|
| Net Income | −$257M | +77% | Q1 2026 |
| EPS | −$3.87 | +68% | Q1 2026 |
| ROE | −75% | n/a | Q1 2026 |
| ROA | −52% | n/a | Q1 2026 |
| ROIC | −305% | n/a | Q1 2026 |
| Free Cash Flow | −$224M | +60% | Q1 2026 |
Every figure straight from the statements as filed with the SEC, no scoring, no adjustment. Open a series for its full history.
MoonLake Immunotherapeutics (MLTX) - Net IncomeNet IncomeMoonLake Immunotherapeutics (MLTX)